vs
ICU MEDICAL INC（ICUI）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Revolve Group, Inc.的1.7倍（$540.7M vs $324.4M），Revolve Group, Inc.净利率更高（5.7% vs -2.9%，领先8.6%），Revolve Group, Inc.同比增速更快（10.4% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-13.3M），过去两年Revolve Group, Inc.的营收复合增速更高（9.5% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
ICUI vs RVLV — 直观对比
营收规模更大
ICUI
是对方的1.7倍
$324.4M
营收增速更快
RVLV
高出24.6%
-14.1%
净利率更高
RVLV
高出8.6%
-2.9%
自由现金流更多
ICUI
多$49.2M
$-13.3M
两年增速更快
RVLV
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $324.4M |
| 净利润 | $-15.7M | $18.6M |
| 毛利率 | 37.5% | 53.3% |
| 营业利润率 | 1.0% | 6.3% |
| 净利率 | -2.9% | 5.7% |
| 营收同比 | -14.1% | 10.4% |
| 净利润同比 | 34.0% | 50.4% |
| 每股收益（稀释后） | $-0.63 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIRVLV
| Q4 25 | $540.7M | $324.4M | ||
| Q3 25 | $537.0M | $295.6M | ||
| Q2 25 | $548.9M | $309.0M | ||
| Q1 25 | $604.7M | $296.7M | ||
| Q4 24 | $629.8M | $293.7M | ||
| Q3 24 | $589.1M | $283.1M | ||
| Q2 24 | $596.5M | $282.5M | ||
| Q1 24 | $566.7M | $270.6M |
净利润ICUIRVLV
| Q4 25 | $-15.7M | $18.6M | ||
| Q3 25 | $-3.4M | $21.2M | ||
| Q2 25 | $35.3M | $10.2M | ||
| Q1 25 | $-15.5M | $11.8M | ||
| Q4 24 | $-23.8M | $12.3M | ||
| Q3 24 | $-33.0M | $11.0M | ||
| Q2 24 | $-21.4M | $15.4M | ||
| Q1 24 | $-39.5M | $10.9M |
毛利率ICUIRVLV
| Q4 25 | 37.5% | 53.3% | ||
| Q3 25 | 37.4% | 54.6% | ||
| Q2 25 | 37.9% | 54.1% | ||
| Q1 25 | 34.7% | 52.0% | ||
| Q4 24 | 36.1% | 52.5% | ||
| Q3 24 | 34.8% | 51.2% | ||
| Q2 24 | 34.8% | 54.0% | ||
| Q1 24 | 32.7% | 52.3% |
营业利润率ICUIRVLV
| Q4 25 | 1.0% | 6.3% | ||
| Q3 25 | 2.6% | 7.1% | ||
| Q2 25 | 1.9% | 5.8% | ||
| Q1 25 | 2.1% | 5.0% | ||
| Q4 24 | 6.0% | 3.9% | ||
| Q3 24 | 1.4% | 5.0% | ||
| Q2 24 | 1.3% | 5.8% | ||
| Q1 24 | -1.9% | 3.4% |
净利率ICUIRVLV
| Q4 25 | -2.9% | 5.7% | ||
| Q3 25 | -0.6% | 7.2% | ||
| Q2 25 | 6.4% | 3.3% | ||
| Q1 25 | -2.6% | 4.0% | ||
| Q4 24 | -3.8% | 4.2% | ||
| Q3 24 | -5.6% | 3.9% | ||
| Q2 24 | -3.6% | 5.4% | ||
| Q1 24 | -7.0% | 4.0% |
每股收益（稀释后）ICUIRVLV
| Q4 25 | $-0.63 | $0.27 | ||
| Q3 25 | $-0.14 | $0.29 | ||
| Q2 25 | $1.43 | $0.14 | ||
| Q1 25 | $-0.63 | $0.16 | ||
| Q4 24 | $-0.97 | $0.18 | ||
| Q3 24 | $-1.35 | $0.15 | ||
| Q2 24 | $-0.88 | $0.21 | ||
| Q1 24 | $-1.63 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $292.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $512.5M |
| 总资产 | $4.1B | $765.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIRVLV
| Q4 25 | — | $292.3M | ||
| Q3 25 | — | $315.4M | ||
| Q2 25 | — | $310.7M | ||
| Q1 25 | — | $300.8M | ||
| Q4 24 | $308.6M | $256.6M | ||
| Q3 24 | $312.5M | $252.8M | ||
| Q2 24 | $302.6M | $244.7M | ||
| Q1 24 | $251.4M | $273.4M |
股东权益ICUIRVLV
| Q4 25 | $2.1B | $512.5M | ||
| Q3 25 | $2.1B | $490.2M | ||
| Q2 25 | $2.1B | $468.6M | ||
| Q1 25 | $2.0B | $453.4M | ||
| Q4 24 | $2.0B | $437.8M | ||
| Q3 24 | $2.0B | $420.8M | ||
| Q2 24 | $2.0B | $405.8M | ||
| Q1 24 | $2.1B | $389.9M |
总资产ICUIRVLV
| Q4 25 | $4.1B | $765.0M | ||
| Q3 25 | $4.1B | $751.3M | ||
| Q2 25 | $4.1B | $722.9M | ||
| Q1 25 | $4.2B | $713.9M | ||
| Q4 24 | $4.2B | $665.5M | ||
| Q3 24 | $4.3B | $670.9M | ||
| Q2 24 | $4.3B | $657.8M | ||
| Q1 24 | $4.3B | $650.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $-13.3M |
| 自由现金流率自由现金流/营收 | 6.6% | -4.1% |
| 资本支出强度资本支出/营收 | 4.6% | 1.0% |
| 现金转化率经营现金流/净利润 | — | -0.55× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $48.0M |
8季度趋势，按日历期对齐
经营现金流ICUIRVLV
| Q4 25 | $60.6M | $-10.2M | ||
| Q3 25 | $56.7M | $11.8M | ||
| Q2 25 | $11.2M | $12.6M | ||
| Q1 25 | $51.3M | $45.1M | ||
| Q4 24 | $40.2M | $3.9M | ||
| Q3 24 | $36.1M | $9.1M | ||
| Q2 24 | $82.0M | $-24.7M | ||
| Q1 24 | $45.8M | $38.4M |
自由现金流ICUIRVLV
| Q4 25 | $36.0M | $-13.3M | ||
| Q3 25 | $27.6M | $7.5M | ||
| Q2 25 | $-8.5M | $10.4M | ||
| Q1 25 | $36.7M | $43.4M | ||
| Q4 24 | $16.1M | $2.1M | ||
| Q3 24 | $16.2M | $8.0M | ||
| Q2 24 | $62.5M | $-25.7M | ||
| Q1 24 | $29.9M | $36.7M |
自由现金流率ICUIRVLV
| Q4 25 | 6.6% | -4.1% | ||
| Q3 25 | 5.1% | 2.5% | ||
| Q2 25 | -1.5% | 3.4% | ||
| Q1 25 | 6.1% | 14.6% | ||
| Q4 24 | 2.6% | 0.7% | ||
| Q3 24 | 2.7% | 2.8% | ||
| Q2 24 | 10.5% | -9.1% | ||
| Q1 24 | 5.3% | 13.5% |
资本支出强度ICUIRVLV
| Q4 25 | 4.6% | 1.0% | ||
| Q3 25 | 5.4% | 1.5% | ||
| Q2 25 | 3.6% | 0.7% | ||
| Q1 25 | 2.4% | 0.6% | ||
| Q4 24 | 3.8% | 0.6% | ||
| Q3 24 | 3.4% | 0.4% | ||
| Q2 24 | 3.3% | 0.4% | ||
| Q1 24 | 2.8% | 0.6% |
现金转化率ICUIRVLV
| Q4 25 | — | -0.55× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | 0.32× | 1.24× | ||
| Q1 25 | — | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | — | 3.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
